Dear DEA.
نویسندگان
چکیده
“Dear DEA” is a series of five clinical vignettes intended to address common concerns of clinicians and to demonstrate the cooperation of the Drug Enforcement Administration (DEA) with health professionals. The DEA is available to clarify the federal regulations on legally prescribing controlled substances to patients. It is essential that prescribing clinicians understand the federal regulations that address administering, prescribing, and dispensing scheduled controlled substances whether they treat patients in a medical office, a hospital, a long-term care facility, or a hospice setting. This information is necessary not only to reduce diversion and misuse of controlled substances but also to protect the clinicians’ abilities to provide care. It may be equally important for clinicians to have sufficient comfort with their knowledge that they do not invariably “err on the side of caution” and thereby provide inadequate care. The government’s role regarding controlled substances is determined by dual imperatives and the central principle of “balance.” One mandate is to establish a system of controls to prevent misuse and diversion of controlled substances. The second mandate is to ensure the availability of controlled substances for medical and scientific purposes and for these medications to be accessible to all patients who need them [1]. The following vignettes describe situations in which clinician uncertainty had the potential to adversely affect practice. Each case was resolved by prompt and clear information provided by Patricia M. Good, Chief, Liaison and Policy Section, Office of Diversion Control, DEA, Washington DC.
منابع مشابه
Dear DEA
Dear DEA [2] Description: This series of five clinical vignettes focuses on common concerns of clinicians and illustrates the relationship between the Drug Enforcement Administration (DEA) and health professionals, noting that the DEA can help explain federal regulations on legally prescribing controlled substances to patients. Authors: Heit HA, Covington E, Good PM. Source: Pain Medicine field...
متن کاملSuper-Efficiency DEA Approach for Optimizing Multiple Quality Characteristics in Parameter Design
This paper proposes an efficient approach for optimizing the multiple quality characteristics (QCHs) in manufacturing applications on the Taguchi method using the super efficiency technique in data envelopment analysis (DEA). Each experiment in Taguchi’s orthogonal array (OA) is treated as a decision making unit (DMU) with multiple QCHs set as inputs or outputs. DMU’s efficiency is evaluated th...
متن کاملDEA 1 Expression on Dog Erythrocytes Analyzed by Immunochromatographic and Flow Cytometric Techniques
BACKGROUND The Dog erythrocyte antigen (DEA) 1 blood group system was thought to contain types DEA 1.1 and 1.2 (and possibly 1.3 [A3]). However, DEA 1.2+ dogs are very rare and newer typing methods reveal varying degrees of DEA 1 positivity. OBJECTIVES To assess if variation in DEA 1 positivity is because of quantitative differences in surface antigen expression. To determine expression patte...
متن کاملNetwork DEA pitfalls: Divisional efficiency and frontier projection under general network structures
Data envelopment analysis (DEA) is a method for measuring the efficiency of peer decision making units (DMUs). Recently network DEA models been developed to examine the efficiency of DMUs with internal structures. The internal network structures range from a simple two-stage process to a complex system where multiple divisions are linked together with intermediate measures. In general, there ar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Pain medicine
دوره 5 3 شماره
صفحات -
تاریخ انتشار 2004